|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Zeng H, Zhang S and He J:
Annual report on status of cancer in China, 2011. Chin J Cancer
Res. 27:2–12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nagtegaal ID, Quirke P and Schmoll HJ: Has
the new TNM classification for colorectal cancer improved care? Nat
Rev Clin Oncol. 9:119–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Raaijmakers JH and Bos JL: Specificity in
Ras and Rap signaling. J Biol Chem. 284:10995–10999. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Polakis P, Rubinfeld B and McCormick F:
Phosphorylation of rap1GAP in vivo and by cAMP-dependent kinase and
the cell cycle p34cdc2 kinase in vitro. J Biol Chem.
267:10780–10785. 1992.PubMed/NCBI
|
|
6
|
Bos JL, de Rooij J and Reedquist KA: Rap1
signalling: Adhering to new models. Nat Rev Mol Cell Biol.
2:369–377. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tsygankova OM, Feshchenko E, Klein PS and
Meinkoth JL: Thyroid-stimulating hormone/cAMP and glycogen synthase
kinase 3beta elicit opposing effects on Rap1GAP stability. J Biol
Chem. 279:5501–5507. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang L, Chenwei L, Mahmood R, van Golen
K, Greenson J, Li G, D'Silva NJ, Li X, Burant CF, Logsdon CD and
Simeone DM: Identification of a putative tumor suppressor gene
RaplGAP in pancreatic cancer. Cancer Res. 66:898–906. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsygankova OM, Prendergast GV, Puttaswamy
K, Wang Y, Feldman MD, Wang H, Brose MS and Meinkoth JL:
Downregulation of Rap1GAP contributes to Ras transformation. Mol
Cell Biol. 27:6647–6658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zuo H, Gandhi M, Edreira MM, Hochbaum D,
Nimgaonkar VL, Zhang P, Dipaola J, Evdokimova V, Altschuler DL and
Nikiforov YE: Downregulation of RaplGAP through epigenetic
silencing and loss of heterozygosity promotes invasion and
progression of thyroid tumors. Cancer Res. 70:1389–1397. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dong X, Tang W, Stopenski S, Brose MS,
Korch C and Meinkoth JL: RAP1GAP inhibits cytoskeletal remodeling
and motility in thyroid cancer cells. Endocr Relat Cancer.
19:575–588. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Z, Mitra RS, Henson BS, Datta NS,
McCauley LK, Kumar P, Lee JS, Carey TE and D'Silva NJ: Rap1GAP
inhibits tumor growth in oropharyngeal squamous cell carcinoma. Am
J Pathol. 168:585–596. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zheng H, Gao L, Feng Y, Yuan L, Zhao H and
Cornelius LA: Down-regulation of Rap1GAP via promoter
hypermethylation promotes melanoma cell proliferation, survival,
and migration. Cancer Res. 69:449–457. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qiu T, Qi X, Cen J and Chen Z: Rap1GAP
alters leukemia cell differentiation, apoptosis and invasion in
vitro. Oncol Rep. 28:622–628. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bailey CL, Kelly P and Casey PJ:
Activation of Rap1 promotes prostate cancer metastasis. Cancer Res.
69:4962–4968. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vuchak LA, Tsygankova OM and Meinkoth JL:
Rap1GAP impairs cell-matrix adhesion in the absence of effects on
cell-cell adhesion. Cell Adh Migr. 5:323–331. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Banerjee R, Mani RS, Russo N, Scanlon CS,
Tsodikov A, Jing X, Cao Q, Palanisamy N, Metwally T, Inglehart RC,
et al: The tumor suppressor gene rap1GAP is silenced by
miR-101-mediated EZH2 overexpression in invasive squamous cell
carcinoma. Oncogene. 30:4339–4349. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tsygankova OM, Wang H and Meinkoth JL:
Tumor cell migration and invasion are enhanced by depletion of Rap1
GTPase-activating protein (Rap1GAP). J Biol Chem. 288:24636–24646.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tamate M, Tanaka R, Osogami H, Matsuura M,
Satohisa S, Iwasaki M and Saito T: Rap1GAP inhibits tumor
progression in endometrial cancer. Biochem Biophys Res Commun.
485:476–483. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang Y, Zhang J, Yan Y, Cai H, Li M, Sun
K, Wang J, Liu X, Wang J and Duan X: Low expression of Rap1GAP is
associated with epithelial-mesenchymal transition (EMT) and poor
prognosis in gastric cancer. Oncotarget. 8:8057–8068.
2017.PubMed/NCBI
|
|
21
|
Tsygankova OM, Ma C, Tang W, Korch C,
Feldman MD, Lv Y, Brose MS and Meinkoth JL: Downregulation of
Rap1GAP in human tumor cells alters cell/matrix and cell/cell
adhesion. Mol Cell Biol. 30:3262–3274. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nelson AR, Fingleton B, Rothenberg ML and
Matrisian LM: Matrix metalloproteinases: Biologic activity and
clinical implications. J Clin Oncol. 18:1135–1149. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li CY, Yuan P, Lin SS, Song CF, Guan WY,
Yuan L, Lai RB, Gao Y and Wang Y: Matrix metalloproteinase 9
expression and prognosis in colorectal cancer: A meta-analysis.
Tumour Biol. 34:735–741. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Herszényi L, Hritz I, Lakatos G, Varga MZ
and Tulassay Z: The behavior of matrix metalloproteinases and their
inhibitors in colorectal cancer. Int J Mol Sci. 13:13240–13263.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zuzga DS, Gibbons AV, Li P, Lubbe WJ,
Chervoneva I and Pitari GM: Overexpression of matrix
metalloproteinase 9 in tumor epithelial cells correlates with
colorectalcancer metastasis. Clin Transl Sci. 1:136–141. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mitra RS, Goto M, Lee JS, Maldonado D,
Taylor JM, Pan Q, Carey TE, Bradford CR, Prince ME, Cordell KG, et
al: Rap1GAP promotes invasion via induction of matrix
metalloproteinase 9 secretion, which is associated with poor
survival in low N-stage squamous cell carcinoma. Cancer Res.
68:3959–3969. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hur K, Toiyama Y, Takahashi M, Balaguer F,
Nagasaka T, Koike J, Hemmi H, Koi M, Boland CR and Goel A:
MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT)
in human colorectal cancer metastasis. Gut. 62:1315–1326. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brabletz T, Hlubek F, Spaderna S,
Schmalhofer O, Hiendlmeyer E, Jung A and Kirchner T: Invasion and
metastasis in colorectal cancer: Epithelial-mesenchymal transition,
mesenchymal-epithelial transition, stem cells and beta-catenin.
Cells Tissues Organs. 179:56–65. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Arias AM: Epithelial mesenchymal
interactions in cancer and development. Cell. 105:425–431. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Onder TT, Gupta PB, Mani SA, Yang J,
Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis
via multiple downstream transcriptional pathways. Cancer Res.
68:3645–3654. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Perl AK, Wilgenbus P, Dahl U, Semb H and
Christofori G: A causal role for E-cadherin in the transition from
adenoma to carcinoma. Nature. 392:190–193. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tsai JH and Yang J: Epithelial-mesenchymal
plasticity in carcinoma metastasis. Genes Dev. 27:2192–2206. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsanou E, Peschos D, Batistatou A,
Charalabopoulos A and Charalabopoulos K: The E-cadherin adhesion
molecule and colorectal cancer. A global literature approach.
Anticancer Res. 28:3815–3826. 2008.PubMed/NCBI
|
|
37
|
Kwak JM, Min BW, Lee JH, Choi JS, Lee SI,
Park SS, Kim J, Um JW, Kim SH and Moon HY: The prognostic
significance of Ecadherin and liver intestine-cadherin expression
in colorectal cancer. Dis Colon Rectum. 50:1873–1880. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hiscox S and Jiang WG: Expression of
E-cadherin, alpha, beta and gamma-catenin in human colorectal
cancer. Anticancer Res. 17:1349–1354. 1997.PubMed/NCBI
|
|
39
|
Rosivatz E, Becker I, Bamba M, Schott C,
Diebold J, Mayr D, Höfler H and Becker KF: Neoexpression of
N-cadherin in E-cadherin positive colon cancers. Int J Cancer.
111:711–719. 2004. View Article : Google Scholar : PubMed/NCBI
|
